Abstract
The description of the incretin effect was first described in 1964 by Elwick when he observed a greater insulin secretory response if glucose was administered orally compared to intravenously despite similar elevations in plasma glucose. This incretin effect is attributed to the release of peptide hormones from the K and L cells in the intestines in the response to eating, so that approximately 60% of the insulin subsequently secreted is related directly to the effect of incretins [1]. Glucagon like peptide-1 (GLP-1) is secreted by the L cells, suppresses postprandial glucagon secretion, reduces appetite and stimulates insulin secretion in a dose dependent manner.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nauck M. Unraveling the science of indretin biology. Am J Med. 2009;122(6A):S3–S24.
Drucker DJ, Nauck MA. The incretin system. Lancet. 2006;368:1696–1705.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
Eissele R, Goke R, Willemer S. Glucagon like peptide cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest. 1992;22:283–291.
Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon like peptide-1 in the pathogenesis of type-2 diabetes. Diabetes. 2004;53(suppl 3):S190–S196.
Nauck MA, Stockman F, Ebert R, Creutzfeldt W. Reduced incretin effect in type-2 diabetes. Diabetologia. 1986;29:46–52.
Meier JJ, Goetze O, Anstipp J. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab. 2004:286:E621–E625.
Li Y, Cao X, Li LX. Beta cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes. 2005;54:482–491.
Meier JJ, Gallwitz B, Kask B. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptidein patients with type-2 diabetes and healthy control subjects. Diabetes. 2004;53(suppl 3):S220–S224.
Nauck MA. Glucagon-like peptide-1 in type-2 diabetes: the beta cell and beyond. Diabetes Obes Metab. 2008;10(suppl 3):2–13.
Cervera A, Wajcberg E, Sriwijitkamol A. Mechanism of action of exenatide treatment on A1C, weight and cardiovascular risk factors. Diabetes Obes Metab. 2006;8:436–447.
Nielsen L, Baron A, Pharmacology of exenatide for the treatment of type-2 diabetes. Curr Opin Investig Drugs. 2003;4:401–405.
Kolterman O, Kim DD, Shen L. Pharmacokinetics, pharmacodynamics and safety of exenatide in patients with type-2 diabetes mellitus. Am Health Syst Pharm. 2005;62:173–181.
Kendall DM, Riddle MC, Rosenstock J. effects of exenatide on glycemic control over 30 weeks in patients with type-2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–1091.
Heine RJ, Van Gaal LF, Johns D. Exenatide versus insulin glargine in patients with suboptimally controlled type-2 diabetes. Ann Intern Med. 2005;143:559–569.
Buse JB, Klonoff DC, Nielson LL. Metabolic effect of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type-2 diabetes. Clin Ther. 2007;29:139–153.
Nauck MA, Duran S, Kim D. A comparison of twice daily exenatide and biphasic insulin aspart in patients with type-2 diabetes who were suboptimally controlled with sulfonylurea and metformin. Diabetologia. 2007;50:259–267.
Barnett AH, Trautmann M, Burger J, Johns D, Kim D, Brodows R, Festa A. A comparison of exenatide and insulin glargine in patients using a single oral diabetic agent. Data disclosure at the 42 annual meeting of the European Association of Diabetes. September 16, 2006.
Heine R, Van Gaal L, Johns D, Mihm M. Exenatide versus insulin glargine in patients with suboptimally controlled type-2 diabetes. Ann Intern Med. 2005;143(8):559–569.
Cure P. Exenatide and adverse events. New Engl J Med. 2008;358:1969–1972.
Zinman B, Hoogwerf BJ, Duran J, Garcia S. the effect of adding exenatide to a thiazolidinedione in suboptimally controlled type-2 diabetes. Ann Intern Med. 2007;146:477–485.
Briceno RM, Lagari-Libhaber VS. Meneghini LF. Clinical observations study of the safety, effectiveness, and tolerability of exenatide in a real world setting. Diabetes. 2007;56(suppl 1):Abstract 2147-PO.
Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL. One year treatment with exenatide improves beta cell function compared with insulin glargine in metformin treated type-2 diabetic patients. Diabetes Care. 2009;32(5):762–768.
Drucker DJ, Buse KB, Taylor K, Kendall DM. Exenatide once weekly versus twice daily for the treatment of type-2 diabetes. Lancet. 2008;372(9645):1240–1250.
Vilsboll T, Zdravkovic M, Le-Thi T. Liraglutide, a long acting human glucagon like peptide-1 analog. Diabetes Care. 2007;30:1608–1610.
Victoza (liraglutide) package insert. Princeton NJ: Novo Nordisk; 2010.
Nauck M, Frid A, Hermansen K. for the LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride and placebo all in combination with metformin in type-2 diabetes: the LEAD-2 study. Diabetes Care. 2009;32(1)84–90.
Buse JB, Rosenstock J, Sesti G. Liraglutide once a day versus exenatide twice a day for type-2 diabetes: a 26 week randomized, parallel group, multinational open label trial (LEAD-6). Lancet. 2009;374:39–47.
Garber A, Henry R, Ratner R. Liraglutide versus glimepiride monotherapy for type-2 diabetes (LEAD-3). Lancet. 2009;373:473–481.
Merani S, Truong W, Emamaullee JA, Toso C, Knudsen LB. Liraglutide improves glucose homeostasis in marginal mass islet transplantation in mice. Endocrinology. 2008;149(9):4322–4328.
Mari A, Degn K, Brock B. Effects of the long acting human glucagon like peptide-1 analog liraglutide on beta cell function in normal living conditions. Diabetes Care. 2007;30:2032–2033.
Kruger DF, Gatacomb PM, Owen Sk. Clinical implication of amylin and amylin deficiency. Diabetes Educ. 1999;25:389–398.
Gedulin BR, Rink TJ, Young AA. Dose response for the glucagonostatic effect of amylin in rats. Metabolism. 1997;46:67–70.
Beeley NRA, Prickett KS. The amylin, CGRP and calcitonin family of peptides. Expert Opin Ther Pat. 1996:6:555–567.
Young A. Amylin’s physiology and its role in diabetes. Curr Opin Endocrinol Diabetes. 1997;4:282–290.
Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol. 2000;278:G946–G951.
Young AA, Vine W, Gedulin BR. Preclinical pharmacology of pramlintide in the rat: comparisons with human an rat amylin. Dur Develop Res. 1996;37:231–248.
Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA. Pramlintide as an adjunct to insulin therapy improves longterm glycemic and weight control in patients with type-2 diabetes. Diabetes Care. 2003;26:784–790.
Wysham C, Lush C, Zhang B, Maier H, Wilhelm K. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type-2 diabetes. Curr Med Res Opin. 2008;24(1):79–85.
Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type-1 and type-2 diabetes mellitus. Clin Ther. 2005;27:1500–1512.
Author information
Authors and Affiliations
Additional information
Diplomate American Board of Internal Medicine
Diplomate American Board of Clinical Lipidology
Diplomate American Board of Vascular Medicine
Clinical Hypertension Specialist (American Society of Hypertension Certified)
Vascular Ultrasound (American Registry of Diagnostic Sonography Certified)
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Codario, R.A. (2011). Non-Insulin Injectables. In: Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-441-8_8
Download citation
DOI: https://doi.org/10.1007/978-1-60327-441-8_8
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-440-1
Online ISBN: 978-1-60327-441-8
eBook Packages: MedicineMedicine (R0)